CommercialCoverageLow impact
08.01.26d, Enzyme Replacement Therapy for Adenosine Deaminase Severe Combined Immune Deficiency (e.g., elapegademase-lvlr [Revcovi])
Independence Blue Cross·Allergy & Immunology, Pediatrics, Oncology·Medical Policy
Effective date
Nov 26, 2025
We identified it
Jun 19, 2026
Summary
Insurance policy for enzyme replacement therapy using elapegademase-lvlr (Revcovi) for Adenosine Deaminase Severe Combined Immune Deficiency has been reissued with updates. This affects billing and coverage for this rare genetic disorder treatment.
Action Required
By November 26, 2025: Billing team should review the full updated policy at the provided URL to understand any changes to coverage criteria, prior authorization requirements, or billing guidelines for elapegademase-lvlr (Revcovi). Update billing protocols accordingly for this rare enzyme replacement therapy.